Searching for Solutions

Stephen R. Saklad, PharmD, BCPP, Senior Editor Joshua Caballero, PharmD, BCPP, Senior Editor Rex S. Lott, PharmD, BCPP, Board Liaison Mary C. Borovicka, PharmD, BCPP, BCPS Stephen S Caruana, PharmD, BCPS Robin N. Hieber, PharmD, BCPP Tiffany-Jade Kreys, PharmD Raymond Lorenz, PharmD, BCPP Stephanie V. Phan, PharmD, BCPP Amy Werremeyer, PharmD, BCPP

Stephen R. Saklad, PharmD, BCPP, Senior Editor Joshua Caballero, PharmD, BCPP, Incoming Senior Editor Jerry R. McKee, PharmD, BCPP, MS, Board Liaison Mary C. Borovicka, PharmD, BCPP, BCPS Stephen S Caruana, PharmD, BCPS Robin N. Hieber, PharmD, BCPP Tiffany-Jade Kreys, PharmD Raymond Lorenz, PharmD, BCPP Stephanie V. Phan, PharmD, BCPP Amy Werremeyer, PharmD, BCPP

As a poster presenter at the CPNP Annual Meeting, you have already taken the important first steps in conducting research, identifying best practices, or critically analyzing some other aspect of neuropsychiatric pharmacotherapy. Presenting a poster at the CPNP Annual Meeting provided a forum to discuss your findings with many active professionals in the specialty.

The Mental Health Clinician attempts to provide interesting and useful insights in the field of neuropsychiatric pharmacy. Contributors can deviate from these basic types of articles, but the guidelines are provided below to help jumpstart new articles. For other ideas of articles that might be appropriate, see the NIH list of common article types.

We at AAPP envision a world where every individual with a psychiatric disorder has a care team that includes a psychiatric pharmacist accountable for optimal medication therapy. In much the same way, AAPP hopes to make a real impact by being part of a team of organizations who share a common vision of patient care and the profession. We encourage you to further investigate these partnerships to learn more about how AAPP is working to make an impact.

VitalSource is a leading provider of e-textbook solutions. AAPP provides some of its educational resources through VitalSource to all users to read and annotate the document from nearly any device. It is more convenient than managing a library of PDFs, and it is more accessible than only viewing them online.

AAPP Communities and the associated discussion threads and email list functionality are available to current AAPP members for the purpose of communicating with other AAPP members on matters regarding psychiatric and neurologic pharmacy or medical issues.

AAPP is a member-driven organization, and we currently support several technologies that facilitate the free exchange of information among pharmacists and other health care professionals. To promote a safe, friendly and professional environment, we have documented acceptable behavior and use of data. Please take a moment to read the following terms of use:

Whether you are a current or aspiring BCPP, the graphic below is meant to help you to identify your professional development options as it relates to AAPP's BCPP prepartory and BCPP products. Simply click on the graphic and you will be linked to more information on the available products.

The American Association of Psychiatric Pharmacists (AAPP) has created this policy in order to document our ongoing commitment to privacy. This policy will help you to understand how personally identifiable information is obtained and how such information may be shared.

Clozapine REMS Advocacy Continues – Join Us for Updates on March 18

The minutes of the November 19, 2024, FDA joint advisory committee meeting have been posted. As previously reported, this meeting was called to discuss reevaluation of the Clozapine Risk Evaluation and Mitigation Strategy (REMS) and possible changes to minimize burden on patients, pharmacies, and prescribers while maintaining safe use of clozapine. With the joint FDA advisory committees overwhelmingly voting to eliminate the risk evaluation and mitigation strategy (REMS), AAPP has continued its advocacy on the REMS in conjunction with partners such as the American Psychiatric Association, Angry Moms, the Schizophrenia and Psychosis Alliance, and more. AAPP has earmarked March 18 at 10 AM central time for a webinar to update members on our advocacy and to discuss practice implications should the REMS be eliminated. More information and registration forthcoming!
Learn More

Our Mission As the philanthropic arm of AAPP, our mission is to advance the psychiatric pharmacy profession by supporting research, scholarship, and practitioner development. The Foundation’s mission complements that of our affiliated association, the American Association of Psychiatric Pharmacists (AAPP), which focuses on serving psychiatric pharmacists and aspiring psychiatric pharmacists and advancing their reach and practice.

Combatting Stigma with Education and Research Mental Health First Aid Training

With your help, the AAPP Foundation can improve access to effective and compassionate care for individuals living with mental illness. This will be accomplished through our initiatives including research, scholarship, and practitioner development of psychiatric pharmacists.